Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19).
Adenine
/ therapeutic use
Adult
Anti-HIV Agents
/ therapeutic use
Drug Interactions
Emtricitabine
/ therapeutic use
Female
HIV Infections
/ drug therapy
HIV Seropositivity
/ drug therapy
Humans
Male
Middle Aged
Retrospective Studies
Reverse Transcriptase Inhibitors
SARS-CoV-2
Tenofovir
/ adverse effects
COVID-19 Drug Treatment
HIV
combination antiretroviral therapy
coronavirus disease 2019 (COVID-19)
drug-drug interaction
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
10
10
2021
received:
24
08
2021
accepted:
16
11
2021
pubmed:
4
12
2021
medline:
10
6
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
The aim of this international multicentre study was to review potential drug-drug interactions (DDIs) for real-life coadministration of combination antiretroviral therapy (cART) and coronavirus disease 2019 (COVID-19)-specific medications. The Euroguidelines in Central and Eastern Europe Network Group initiated a retrospective, observational cohort study of HIV-positive patients diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data were collected through a standardized questionnaire and DDIs were identified using the University of Liverpool's interaction checker. In total, 524 (94.1% of 557) patients received cART at COVID-19 onset: 117 (22.3%) were female, and the median age was 42 (interquartile range 36-50) years. Only 115 (21.9%) patients were hospitalized, of whom 34 required oxygen therapy. The most frequent nucleoside reverse transcriptase inhibitor (NRTI) backbone was tenofovir disoproxil fumarate (TDF)/tenofovir alafenamide (TAF) with lamivudine or emtricitabine (XTC) (79.3%) along with an integrase strand transfer inhibitor (INSTI) (68.5%), nonnucleoside reverse transcriptase inhibitor (NNRTI) (17.7%), protease inhibitor (PI) (13.7%) or other (2.5%). In total, 148 (28.2%) patients received COVID-19-specific treatments: corticosteroids (15.7%), favipiravir (7.1%), remdesivir (3.1%), hydroxychloroquine (2.7%), tocilizumab (0.6%) and anakinra (0.2%). In total, 62 DDI episodes were identified in 58 patients (11.8% of the total cohort and 41.9% of the COVID-19-specific treatment group). The use of boosted PIs and elvitegravir accounted for 43 DDIs (29%), whereas NNRTIs were responsible for 14 DDIs (9.5%). In this analysis from the Central and Eastern European region on HIV-positive persons receiving COVID-19-specific treatment, it was found that potential DDIs were common. Although low-dose steroids are mainly used for COVID-19 treatment, comedication with boosted antiretrovirals seems to have the most frequent potential for DDIs. In addition, attention should be paid to NNRTI coadministration.
Substances chimiques
Anti-HIV Agents
0
Reverse Transcriptase Inhibitors
0
Tenofovir
99YXE507IL
Emtricitabine
G70B4ETF4S
Adenine
JAC85A2161
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-700Informations de copyright
© 2021 British HIV Association.
Références
Kowalska JD, Skrzat-Klapaczynska A, Bursa D, et al. HIV care in times of the COVID-19 crisis-where are we now in Central and Eastern Europe? Int J Infect Dis. 2020;96:311-314.
Gatechompol S, Avihingsanon A, Putcharoen O, et al. COVID-19 and HIV infection co-pandemics and their impact: a review of the literature. AIDS Res Ther. 2021;18:28. doi:10.1186/s12981-021-00335-1
Waterfield KC, Shah GH, Etheredge GD, et al. Consequences of COVID-19 crisis for persons with HIV: the impact of social determinants of health. BMC Public Health. 2021;21:299. doi:10.1186/s12889-021-10296-9
Yendewa AG, Perez JA, Schlick K, Tribout H, McComsey AG. Clinical features and outcomes of coronavirus disease 2019 among people with human immunodeficiency virus in the United States: a multicenter study from a large global health research network (TriNetX), open forum. Infect Dis. 2021;8:ofab272. doi:10.1093/ofid/ofab272
Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113-119. doi:10.1038/s41586-020-2577-1
https://www.bhiva.org/Coronavirus-COVID-19 Accessed July 30, 2021.
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ Accessed July 30, 2021.
Kowalska JD, Oprea C, de Witt S, et al. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. HIV Med. 2017;18:370-375. doi:10.1111/hiv.12436
https://www.hiv-druginteractions.org/ Accessed July 30, 2021.
https://www.covid19-druginteractions.org/ Accessed July 30, 2021.
Hodge C, Marra F, Marzolini C, et al. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother. 2020;75:3417-3424. doi:10.1093/jac/dkaa340
Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23:e25449. doi:10.1002/jia2.25449
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693-704. doi:10.1056/NEJMoa2021436
Ma S, Xu C, Liu S, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Sig Transduct Target Ther. 2021;6:83. doi:10.1038/s41392-021-00521-7
Sharma M, Saravolatz LD. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor. J Antimicrob Chemother. 2013;68:250-256. doi:10.1093/jac/dks404
Peyro-Saint-Paul L, Besnier P, Demessine L, et al. Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids: a case-control study in the French pharmacovigilance database. J Antimicrob Chemother. 2019;74:3291-3294. doi:10.1093/jac/dkz324
Alam S, Kamal TB, Sarker MMR, Zhou JR, Rahman SMA, Mohamed IN. Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021. Front Pharmacol. 2021;12:659577. doi:10.3389/fphar.2021.659577
Brandariz-Nuñez D, Correas-Sanahuja M, Guarc E, Picón R, García B, Gil R. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. Med Clin (Engl Ed). 2020;155:281-287. doi:10.1016/j.medcle.2020.06.012
Bahap M, Kara E, Sain GG. Fighting on two fronts: drug-drug interactions in people living with HIV infected with SARS-CoV-2. Eur J Hosp Pharm. 2021;28:e3.